CD38: A Target in Relapsed/Refractory Acute Lymphoblastic Leukemia—Limitations in Treatment and Diagnostics

Scientists treated five patients suffering from relapsed acute lymphoblastic leukemia (ALL) with daratumumab. Four patients had T ALL, three of whom achieved complete remission after treatment and underwent stem cell transplant.